Table 3.

Patient disease response

Individual patient dataCohort summary
Day 28Day 56PFSOS
CohortPatientCancer typeDay 28Day 56SDPDPRSDPDPR(median), mo(median), mo
101–001Gastrointestinal stromal tumorPDPD1/3 (33%)2/3 (67%)0/3 (0%)0/3 (0%)2/3 (67%)0/3 (0%)1.03.9
01–002SarcomaSDLTFU
01–003Testicular/sex cord carcinomaPDPD
201–004TCC bladderPDPD1/3 (33%)2/3 (67%)0/3 (0%)0/3 (0%)3/3 (100%)0/3 (0%)0.910.5
01–005SarcomaSDPD
01–006CRCPDPD
301–007CRCSDSD1/3 (33%)2/3 (67%)0/3 (0%)1/3 (33%)2/3 (66%)0/3 (0%)1.98.5
01–008MelanomaPDPD
01–009NSCLCPDPD
401–010CRCSDSD1/3 (33%)1/3 (33%)0/3 (0%)1/3 (33%)1/3 (33%)0/3 (0%)0.93.7
02–013CRCPDPD
01–014NSCLCLTFULTFU
502–020CRCPDPD1/3 (33%)2/3 (67%)0/3 (0%)1/3 (33%)2/3 (67%)0/3 (0%)0.92.7
02–021SCLCSDSD
01–024CRCPDPD
602–022CarcinoidSDSD8/12 (67%)4/12 (33%)0/12 (0%)5/12 (42%)6/12 (50%)0/12 (0%)1.85.8
02–025MelanomaSDN/A
02–026Papillary thyroid carcinomaSDSD
02–027CRCPDPD
02–028CRCSDSD
01–029NETSDSD
02–030CRCSDSD
02–032RCCSDPD
01–033CRCPDPD
02–035Merkel cell carcinomaSDPD
01–036Esophageal carcinomaPDPD
01–038CRCPDPD
701–039NETPDPD4/6 (67%)2/6 (33%)0/6 (0%)4/6 (67%)2/6 (33%)0/6 (0%)4.016.2
02–040Medullary thyroid carcinomaSDSD
01–041NETSDSD
01–042NSCLCSDSD
02–043RCCSDSD
02–044RCCPDPD

Abbreviations: CRC, colorectal carcinoma; LTFU, lost to follow-up; NET, neuroendocrine tumor; NSCLC, non–small cell carcinoma; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; RCC, renal cell carcinoma; SCLC, small cell lung carcinoma; SD, stable disease; TCC, transitional cell carcinoma.